Current and Future Idiopathic Pulmonary Fibrosis Therapy

被引：14

作者：

Richeldi, Luca ^{[1
]}

Baldi, Fabiana ^{[1
]}

Pasciuto, Giuliana ^{[1
]}

Macagno, Francesco ^{[1
]}

Panico, Loredana ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

来源：

AMERICAN JOURNAL OF THE MEDICAL SCIENCES | 2019年 / 357卷 / 05期

关键词：

Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; Clinical trials; TISSUE-GROWTH-FACTOR; SERUM AMYLOID P; V COLLAGEN; PIRFENIDONE; INHIBITOR; CELLS; NINTEDANIB; SURVIVAL; EFFICACY; TRIAL;

D O I：

10.1016/j.amjms.2019.02.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The last years have led to advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF), mainly through the discovery of new pathological pathways and drugs and better design of clinical trials. The objective of this review is both to describe the current therapies approved for the treatment of IPF and the emerging therapeutic approaches. Currently, nintedanib and pirfenidone are the basis of IPF therapy, based on the results of large randomized clinical trials showing their safety and efficacy in reducing disease progression. Nonetheless, the ideal IPF therapy is still lacking and trials are underway to test new therapeutic targets. The near future could bring to clinicians and patients a combined therapeutic strategy, hitting the disease from several simultaneous pathways and hopefully leading to clinical stabilization or improvement.

引用

页码：370 / 373

页数：4

共 30 条

[1] Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis [J].

Chaudhary, N. I. ;

Roth, G. J. ;

Hilberg, F. ;

Mueller-Ouernheim, J. ;

Prasse, A. ;

Zissel, G. ;

Schnapp, A. ;

Park, J. E. .

EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (05) :976-985

[2]

Costabel U, 2014, SARCOIDOSIS VASC DIF, V31, P198

[3] Serum amyloid P: a systemic regulator of the innate immune response [J].

Cox, Nehemiah ;

Pilling, Darrell ;

Gomer, Richard H. .

JOURNAL OF LEUKOCYTE BIOLOGY, 2014, 96 (05) :739-743

[4] Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON [J].

Crestani, Bruno ;

Huggins, John T. ;

Kaye, Mitchell ;

Costabel, Ulrich ;

Glaspole, Ian ;

Ogura, Takashi ;

Song, Jin Woo ;

Stansen, Wibke ;

Quaresma, Manuel ;

Stowasser, Susanne ;

Kreuter, Michael .

LANCET RESPIRATORY MEDICINE, 2019, 7 (01) :60-68

[5] Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis [J].

Desroy, Nicolas ;

Housseman, Christopher ;

Bock, Xavier ;

Joncour, Agnes ;

Bienvenu, Natacha ;

Cherel, Laetitia ;

Labeguere, Virginie ;

Rondet, Emilie ;

Peixoto, Christophe ;

Grassot, Jean-Marie ;

Picolet, Olivier ;

Annoott, Denis ;

Triballeau, Nicolas ;

Monjardet, Alain ;

Wakselman, Emanuelle ;

Roncoroni, Veronique ;

Le Tallec, Sandrine ;

Blanque, Roland ;

Cottereaux, Celine ;

Vandervoort, Nele ;

Christophe, Thierry ;

Mollat, Patrick ;

Lamers, Marieke ;

Auberval, Marielle ;

Hrvacic, Boska ;

Ralic, Jovica ;

Oste, Line ;

van der Aar, Ellen ;

Brys, Reginald ;

Heckmann, Bertrand .

JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (09) :3580-3590

[6] Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis [J].

Dillingh, M. R. ;

van den Blink, B. ;

Moerland, M. ;

van Dongen, M. G. J. ;

Levi, M. ;

Kleinjan, A. ;

Wijsenbeek, M. S. ;

Lupher, M. L., Jr. ;

Harper, D. M. ;

Getsy, J. A. ;

Hoogsteden, H. C. ;

Burggraaf, J. .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2013, 26 (06) :672-676

[7]

Gorina E, 2017, EUR RESPIR J, V50, DOI DOI 10.1183/1393003.CONGRESS-2017.OA3400

[8] A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis [J].

King, Talmadge E., Jr. ;

Bradford, Williamson Z. ;

Castro-Bernardini, Socorro ;

Fagan, Elizabeth A. ;

Glaspole, Ian ;

Glassberg, Marilyn K. ;

Gorina, Eduard ;

Hopkins, Peter M. ;

Kardatzke, David ;

Lancaster, Lisa ;

Lederer, David J. ;

Nathan, Steven D. ;

Pereira, Carlos A. ;

Sahn, Steven A. ;

Sussman, Robert ;

Swigris, Jeffrey J. ;

Noble, Paul W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2083-2092

[9] Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis [J].

Kolb, Martin ;

Raghu, Ganesh ;

Wells, Athol U. ;

Behr, Juergen ;

Richeldi, Luca ;

Schinzel, Birgit ;

Quaresma, Manuel ;

Stowasser, Susanne ;

Martinez, Fernando J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18) :1722-1731

[10] Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF) [J].

Kono, Masato ;

Nakamura, Yutaro ;

Suda, Takafumi ;

Kato, Masato ;

Kaida, Yusuke ;

Hashimoto, Dai ;

Inui, Naoki ;

Hamada, Etsuko ;

Miyazaki, Osamu ;

Kurashita, Syunsuke ;

Fukamachi, Isamu ;

Endo, Koki ;

Ng, Poh-Sing ;

Takehara, Kazuhiko ;

Nakamura, Hirotoshi ;

Maekawa, Masato ;

Chida, Kingo .

CLINICA CHIMICA ACTA, 2011, 412 (23-24) :2211-2215

← 1 2 3 →